Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845816 | 1.00 | LTA4H (0.41) | LTA4HCYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9464275 | 0.82 | — | — | |
| SCHEMBL12093536 | 0.81 | SMN1; SMN2 (0.43) | LTA4HNOS1 | |
| SCHEMBL4840715 | 0.80 | CXCR4 (0.34) | LTA4HSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4840731 | 0.80 | CXCR4 (0.34) | LTA4HSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4781560 | 0.79 | LTA4H (0.38) | LTA4H | |
| SCHEMBL4845985 | 0.78 | — | — | |
| SCHEMBL63739 | 0.78 | — | — | |
| SCHEMBL30115266 | 0.78 | — | — | |
| SCHEMBL3015025 | 0.78 | ALDH1A1 (0.46) | LTA4HNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106478642-A | A kind of method that catalysis prepares 2 methyl triethylene diamines | 吴琦琪 | 2017-03-08 | — | — | CN | claimed |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| CN-209602426-U | One kind isolating and purifying system | SHAOXING XINGXIN NEW MAT CO LTD | 2019-11-08 | — | — | CN | disclosed |
| CN-108997356-A | A method of catalysis Ethylenimine synthesizes 2- methyl triethylene diamine with 2- methyl piperazine | 西安近代化学研究所 | 2018-12-14 | — | — | CN | disclosed |
| CN-108929326-A | A method of using 2- methyl piperazine as Material synthesis 2- methyl triethylene diamine | 西安近代化学研究所 | 2018-12-04 | — | — | CN | disclosed |
| CN-108906116-A | It is a kind of for synthesizing the catalyst and preparation method and application of 2- methyl triethylene diamine | 西安近代化学研究所 | 2018-11-30 | — | — | CN | disclosed |
| CN-106478642-A | A kind of method that catalysis prepares 2 methyl triethylene diamines | 吴琦琪 | 2017-03-08 | — | — | CN | disclosed |
| US-7384934-B2 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1546134-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | ELI LILLY AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0068544-B1 | NOVEL N-ARYL-PIPERAZINEALKANAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-06-03 | — | — | EP | disclosed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084643-A1 | Piperazine substituted aryl benzodiazepines | GABBR1, GABBR2, GABRA5 | LTA4H 4238/4885CYP2D6 279/4885SLC6A2 247/4885 |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDXK, CMPK1, GCK | LTA4H 990/4885CYP2D6 260/4885SLC6A2 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.